IT systems · Practical guide

Veeva Vault Safety validation: testing configuration, case links and releases

In Veeva Safety, enabled applications, local case data, connections and administrative settings determine how a report is processed. Even an unchanged global case can reach a destination differently after a release. The example follows a case update through localisation and the quality system so PV, QA and IT can specify and test the expected outcome.

Table of contents

At a glance

How do you validate Veeva Vault Safety?

Validate the intended PV process in the specific Safety Vault, including enabled functions, roles and connected applications. Trace how incoming information becomes a case, how follow-up data reach local case versions and which version is submitted. Assess Safety changes separately from platform changes. A supplier package or technical acknowledgement alone does not establish that the configured process handles and documents cases correctly.

  • Veeva Safety is an application on Vault; SafetyDocs, Workbench, Signal, and AI for Safety require separate scopes.
  • A common data model does not replace the evaluation of actually activated compounds and rules.
  • The documented Resync function updates existing local cases; it is not a general function for creating new cases.
  • Safety release, platform version, configuration, and subject matter expertise decisions must be consistent within the validation documentation.

1. Distinguish Veeva Safety from its specific PV application use case

The current vendor name is Veeva Safety. The still widely used search term Veeva Vault Safety refers to the same product line on the Vault platform. The product brochure from April 2026 separates ICSR case management from SafetyDocs, Safety Workbench, Safety Signal, and AI for Safety. The fact that these applications originate from a common platform does not imply that each application is included in your contract or scope of operations.

This guide addresses pharmacovigilance for authorized human medicinal products in the EU. Clinical trials, medical devices, and other markets require specific requirements. Although the product range supports multiple areas, a validation approach deemed valid for one area shall not be unreviewedly applied to all other areas.

Maintain alongside the software version the underlying professional regulatory basis. A case validation within the application evaluates a single case; it is not equivalent to demonstrating the suitability of your entire computerised process.

Sources: [1] [8] [12] [9]

2. Create a verifiable map of the actual Vault scope

Separate the productive environment from the test environment. Identify which applications are licensed, which functions are activated, and which configurations are customer-specific. A general description of the Safety Suite does not address these questions. Additionally, for reproducible testing, you will need the relevant user roles and source data.

The following internal planning aid defines the scope based on specific questions. For each line, specify the system owner, the configuration record, and the affected processes. It is not necessary to document all functions of the platform: what is essential are the components in use and those relevant to your operations, including their dependencies.

The Concrete Safety Vault: Application, Configuration, and Verification
AreaScope questionSuitable source record
Safety Application Which inputs, types of cases and reporting channels are used? Approved process scope and actual tenant configuration
Additional Safety Applications What role do SafetyDocs, Workbench, or Signal actually perform? Agreement, activated applications and specified handovers
Localized cases What local datasets and synchronization pathways exist? Configuration of actions and rules for affected data
Compounds Which data is exchanged with Quality or other systems? Active Ingredient, Mapping and Significance of Feedback
Platform and Permissions Which technical functions support the process? Platform access, roles, integration accounts and relevant settings

Sources: [1] [5] [2] [9]

3. Tracking a structured input to the right case

Veeva describes configurable Web Intake Forms for 26R2, whose submitted information is processed as inbox items. The setup help indicates an active safety form connection, a intended user and appropriate permissions. An available function is therefore not yet a fully configured and tested input channel.

Review a used channel from the visible form up to the dataset actually seen by a case handler. Do the field labels, selection values, and entered content match? Is an incomplete entry clearly identifiable? When multiple languages are involved, particular attention must be given to the correct interpretation of the field; a readable interface alone is insufficient.

In advance, define how known cases, new submissions, and information that cannot be clearly categorized should be handled. Submission of an ICSR via a web form does not automatically constitute a professionally valid and final evaluated ICSR. Where your process requires it, the assignment decision must be clearly justifiable.

Sources: [7] [10] [13]

4. Assess data connections based on their meaning in the process

The release documentation 26R2 includes additional feedback on the progress of transferred datasets for the Quality-Safety Connection. This provides visibility into whether an inbox item originating from a QMS complaint has been further processed into a safety case. This status information represents a specific transition between applications.

For your process, it must be clarified what the receiving party is entitled to infer. The notification that a case has arisen does not constitute a general confirmation of completed medical evaluation. Similarly, the handling of a quality complaint does not automatically signify the closure of a PV case. Responsibility for both decisions may be shared, but the rationale must remain clearly and substantively demonstrable.

When connected, check the original identifier, the target reference and the reported meaning. Complete an error: The source has been saved, but the transmission is not yet complete. The team must be able to distinguish this condition from a conscious non-acceptance. You can determine which technical repetition or technical clarification follows on the basis of your actual connection.

Sources: [2] [10]

5. Targeted updates and reconciliation of localized cases

The official Local Case Resync help describes a configurable capability from 26R2 for updating existing foreign-language or foreign Localized Cases with information from the global case. Depending on the process, it can be configured as a user, entry or workflow action. Assess the configuration actually enabled.

The user help specifies a decisive limit: The action updates existing local cases, but does not create new Localized cases. It also describes the adoption of new and modified records as well as the removal of certain datasets and fields that are no longer present in the global case. Therefore, check explicitly separately for adding, changing and removing.

Before a test, describe which contents are to be globally executed and which require local processing. Verify not only that the local dataset is accessible, but also that the required content is correctly present after the action. For local text rules, translations, and pre-generated reports, the appropriate functional description is required. The general synchronization statement does not replace this comparison.

Sources: [5] [6]

6. Test example: Follow-up, local case, and QMS feedback

Example scenario, no executed Veeva test: The test system includes the global case G-073, the existing local case L-073, and the associated QMS dataset Q-088. An additional localisation L-099 was intentionally not created. Cases G-073 and L-073 initially contain the test events E1 and E2.

The verified post-notification confirms E1, corrects its description, and supplements E3. E2 remains explicitly unchanged. The professionally reviewed global target state subsequently contains exactly three events: E1, E2, and E3. For this controlled test configuration, it is specified that the relevant structured event data must align after the configured resync action in L-073. No general overwrite rule is assumed for all local fields.

A previously generated test report version B-01 is separately archived. For the new processing, version B-02 is created only after the intended review. The example requires that the declaration of the prior shipment remain intact. The specific function this evidence provides must be demonstrated by the implementation. An updated local dataset alone does not constitute valid historical report versioning.

Own inspection checklist for the same case across multiple data pathways
Observation pointPredetermined expected resultEvidence and defect inquiry
Global Case G-073 E1 corrected, E2 unchanged, E3 expanded: three events. Source notification and independent pre- and post-comparison; was E2 accidentally removed?
Existing local case L-073 After resynchronisation, the event data specified in the test match G-073. Comparison of all three events and configuration status; did an old value remain?
Localisation L-099 does not exist The Resync action generates no new local case. Inventory reconciliation; is a missing localization incorrectly considered current?
QMS Reference Q-088 Connection to the correct Safety dataset and logically accurate progress status. Compare both sides; could the feedback be misinterpreted as a medical conclusion?
Reports B-01 and B-02 Previous version remains actionable; new message is assigned to B-02. Secure vials, case reference and receipt response; does the ACK constitute the correct message?

Sources: [6] [2] [10]

7. Conduct separate review of medical and technical submissions

A safety system can receive data, evaluate it against formal criteria, and generate reports. However, the medical significance of the information must still be professionally assessed. Specify in the requirement which case scenario is being evaluated, who is responsible for clarifying missing information, and how the decision remains linked to the source used.

ICH E2D(R1) addresses medical case evaluation, follow-up, and duplicate management as distinct tasks. Leverage this differentiation in your review cases. A dataset that remains unchanged may still contain an open scientific question; in contrast, a modified dataset may require a targeted re-evaluation. The technical status alone is insufficient to adequately describe this scenario.

An additional layer is introduced for submissions. A technical ACK must be linked to the correct report and exchange process. It does not signify medical approval by the recipient. Additionally, assess how your team detects and handles missing or negative responses and proceeds with further case processing. A new information may trigger additional work on the case despite a previously acknowledged notification.

Sources: [13] [10] [11]

8. Consider safety release and platform status separately

The Veeva maintenance overview indicates that platform patches for Safety may be released with a time delay relative to Safety patches. Therefore, the general Vault release designation is insufficient for providing a specific and verifiable Safety build. Capture the actual Safety build, the platform version, and relevant configuration details of your environment.

Assign the relevant release information to the affected functions. A mere announcement or publication date does not indicate which version is currently active in your environment.

Assign each relevant change to a corresponding data pathway. Does it affect an incoming mapping, a local update, or merely an unused function? Which prior evidence remains valid, and which test case demonstrates the modified workflow? The published calendar also references a manufacturer validation package. Its specific scope must be evaluated based on the actual content available; a publication date does not answer this question.

Sources: [4] [3] [9]

9. Include rights, historical information, and failure remediation procedures

Verify with the actually intended roles. A case handler, administrator, and integration account do not necessarily require identical access. In particular, for integrated applications, it must be clear whether a change originated from a person, an automated process, or an external takeover. Also test a deliberately missing access, to the extent that it is relevant to the process.

During a data migration, you must define which historical information is required in the new vault and which can remain controlled at another location. Crucially, the traceability of usage must be established: Can the responsible personnel explain a previous assessment, including the source and the report? A counter indicating the number of transferred cases does not answer this question.

In the event of a system outage, assess the operational capacity of PV, IT, and external service providers. How are incoming data entries accepted, how are interim stored information assigned, and how are they reconciled upon system restart? Perform a suitable restart scenario based on your established procedure. Technical availability, completeness of case processing, and historical data accessibility are interrelated but distinct validation outcomes.

Sources: [9] [10] [7]

10. Checklist for Scope, Participation, and Usage Decision

For a SME, costs often arise at organisational transition points: international partners, differing local data versions, external case handling, and multiple Vault owners. First, clarify these variants. The number of licensed applications alone is not a reliable cost estimator.

PV defines technical expectations and appropriate test data. Administrators and IT provide configuration, test access, and connections. QA supports the agreed approach for providing evidence and unresolved findings. Specify who observes changes and initiates an impact assessment; this responsibility must not inadvertently remain unassigned between provider and user.

  • Production Vault, Test environment, Safety Build, and platform version identified.
  • Activated applications, functions, connections, and relevant roles documented.
  • Global, local, and external data ownership responsibilities as described.
  • Independent expectations defined for incoming records, additions, corrections, and missing data sets.
  • Technical ACK, progress update, and expert review clearly distinguished.
  • Existing supplier documentation assigned and additional inspections justified.
  • Historical accessibility, error handling, and system restart practically resolved.
  • Open findings, remaining restrictions and the decision to use them are clearly recorded.

Sources: [9] [10] [4]

Project experience and collaboration

Trace a pharmacovigilance case across a data transfer

Imports, local rules and processing steps can alter a safety case. With the people responsible, we examine a relevant handover and link the incoming information, configuration and version of the case used. We assess the coverage of existing Veeva evidence before planning additional work. Depending on the finding, investigating the handover may suffice, or the changed safety processes may require a wider plan. We document operational responsibilities and outstanding decisions.

Frequently asked questions about Veeva Vault Safety

Is Veeva Vault Safety the same as Veeva Safety?

Veeva designates the current application as Veeva Safety on the Vault platform. For validation, you will additionally require the specific scope of use. SafetyDocs, Workbench, Signal, and AI for Safety are distinct components of the suite. Review the contract and activation prior to considering any function as part of your Safety system.

Sources: [1]

Does the Veeva validation package suffice for our Vault?

Only if its actual coverage aligns with your Vault version, configuration, and process usage. Assign evidence to your specific requirements and document any remaining gaps. Customer-specific integrations, local policies, and custom roles may require additional validation. The public release calendar provides deployment timelines; it does not guarantee that the package fully covers your usage.

Sources: [3] [9]

Must every new Vault function be tested?

First assess whether the function affects your activated application, a technical dependency, or a used data pathway. Only then can the specific evidence requirement be determined. An unused function may be handled differently than a modified mapping for current alerts. Document the rationale and do not confuse lack of knowledge regarding activation with assured non-impact.

Sources: [2] [9]

Does the Local Case Resync feature also resolve missing local cases?

According to the Veeva User Guide, the action updates existing localized cases and does not generate new local cases. Therefore, intentionally omit a local record in an appropriate review case. Your process must be able to detect the absence of a required localization. A successful resync shall not be considered conclusive evidence that all required local cases exist.

Sources: [6]

How do we verify changes to local case information?

Define for each relevant data type which global change is incorporated and which local editing or re-evaluation is required. Compare the cases of addition, modification, and deletion separately. Use the appropriate configuration and functional guidance instead of assuming a single universal synchronization rule. Additionally, existing reports must be evaluated in their original version.

Sources: [5] [6] [10]

Is a Quality-Safety-Progress Status considered a medical release?

No, not automatically. The documented linkage reports specific processing steps between Quality and Safety, and the significance of this information within one's own process must be explicitly described. Verify the identifier, status, and allowed follow-up actions on both sides. The generation of a Safety Case or further processing of a complaint does not automatically signify the completion of all technical evaluations.

Sources: [2] [13]

Why must safety and platform stability be separately documented?

Veeva describes a time-delayed rollout of platform maintenance releases for Safety. Therefore, two environments with similarly named General Releases may require additional environmental details for a specific review. Capture the actual builds and professionally relevant configurations. This enables later assessment of whether a test record aligns with the production environment and which changes require re-evaluation.

Sources: [4]

Can Web Intake Forms be considered complete cases?

The described function initially generates Inbox items for processing. Whether a valid and professionally assessed case emerges from these items depends on available information and the associated process. Therefore, separately evaluate form content, mapping, assignment, and further processing steps. A technical acknowledgment of receipt must not be construed as a general statement regarding case validity, medical review, or reporting obligation.

Sources: [7] [10]

How do we plan effort and internal involvement for a release?

Start with the actually affected data pathways and outstanding validation evidence. Locations, partner integrations, internal configurations, and unclear responsibilities significantly influence effort more than the mere number of new functions. Reserve PV team involvement for intended use values and evaluation, as well as administrative support for test access and configuration. A fixed duration without this scope would not constitute a viable planning basis.

Sources: [3] [4] [9]

What information about the control range do we need prior to a Safety Project?

Maintain documented case types, affected regions, and relevant technical specifications. Identify responsible parties for assessing deadlines, data scope, and submission requirements. Link these determinations to the actual software functions and their configurations utilized. The fact that an application supports multiple report types does not substitute for the clear definition of the respective process.

Sources: [11] [13] [12]

Sources and review date

Source date: 6 October 2026. The referenced releases are documented reference states and do not constitute a statement regarding the status of your vault. Localizations and connections are subject to the actual configuration. Tables and test examples are standalone work aids; they do not represent completed product testing.

  1. Veeva Safety Suite – Product Sheet
  2. What’s New in 26R2 – Safety
  3. About the 26R2 Release
  4. 26R2 Safety Maintenance Releases
  5. Veeva Safety Help: Enable Local Case Resync
  6. Veeva Safety Help: Prepare a Localized Case
  7. Veeva Safety Help: Enable Web Intake Forms
  8. EMA: Good pharmacovigilance practices (GVP)
  9. GVP Module I: Pharmacovigilance systems and their quality systems
  10. GVP Module VI: Collection, management and submission of reports of suspected adverse reactions, Rev. 2
  11. EMA: EudraVigilance – electronic reporting
  12. EMA: ICH E2D post-approval safety data management – Scientific guideline
  13. ICH E2D(R1): Post-Approval Safety Data – Definitions and Standards for Management and Reporting of Individual Case Safety Reports

Sources checked: .

Daniel Herrmann, Daniel Herrmann Consulting

Daniel Herrmann Consulting

Ensure the specific Safety-Vault is traceable and securely protected.

Daniel Herrmann Consulting supports you in consolidating requirements of your PV function, configured data pathways, and existing evidence into a testable validation scope.

  • Cloud and SaaS validation →

    Maintain the validated state of cloud and SaaS systems as suppliers issue new versions. We define the boundary between your responsibilities and the supplier’s and agree how each release will be assessed.

Send a project enquiry Customer testimonials →